<DOC>
	<DOCNO>NCT01446224</DOCNO>
	<brief_summary>This observational study conduct part systematic pharmacovigilance activity , provide population-based context Pazopanib use outside clinical trial setting . The aim study examine incidence cardiovascular ischemia ( include myocardial infarction , unstable angina , transient ischemic attack , cerebrovascular accident ) cardiac arrhythmia ( Torsades de Pointes ) renal cell carcinoma patient treat marketed anti-VEGF agent [ Pazopanib ( VOTRIENT ) , Bevacizumab ( AVASTIN ) , Sorafenib ( NEXAVAR ) , Sunitinib ( SUTENT ) ] . Two database utilized study : large healthcare claim database U.S. Dutch link medical registry ( PHARMO RLS ) . The database provide large , geographically vary , non-trial population examine incidence state cardiovascular ischemic event Torsades de Pointes .</brief_summary>
	<brief_title>Cardiovascular Torsades de Pointes Monitoring Pazopanib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Torsades de Pointes</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>The antiVEGF cohort include patient follow characteristic : Adult patient ( age â‰¥18 year ) Prescribed administer antiVEGF agent : Pazopanib , Bevacizumab , Sorafenib Sunitinib approval date Pazopanib Diagnosed renal cell cancer Patients multiple primary cancer diagnosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>adverse event</keyword>
	<keyword>pazopanib</keyword>
	<keyword>Torsades de Pointes</keyword>
	<keyword>renal cell carcinoma</keyword>
	<keyword>anti-VEGF agent</keyword>
	<keyword>observational data</keyword>
	<keyword>cardiac ischemia</keyword>
</DOC>